Illumina next-generation sequencing (NGS) and microarray technologies represent the gold standard in quality worldwide—and account for ~90% of the world’s sequencing data.* Innovative, intuitive, and completely integrated, our sample-to-data solutions empower your lab to keep ahead of the curve in the rapidly evolving genomics revolution. So you’ll be better able to perform the world-class cancer genomics research you strive for—with the goal of uncovering new insights into the biology of cancer that can lead to meaningful advances in personalized medicine.
Our comprehensive genomics product offerings support multiple cancer research applications, including studies of DNA, RNA, epigenetics, and more. Our range of sequencers can be scaled to meet your needs—from powerful, yet personal, benchtop models to versatile, high-throughput systems. With intuitive data analysis and management capabilities and unsurpassed customer support, we can deliver the answers you seek—quickly, accurately, and cost-effectively.
Explore genomics-based approaches to investigating cancer using NGS and microarrays.
Swetha Anandhan highlights the use of single cell RNA-sequencing to identify a unique population of macrophages in glioblastoma multiforme that persists after treatment with immune checkpoint inhibitors.View Webinar
Advancing precision oncology at the European Congress of Pathology 2021Read Article
Developing and automating best-practice workflows that make analyzing, processing, and disseminating genomic data accessible to researchers and clinicians.Read Interview
Cancer screening gains momentum with $99 million in funding and the country’s largest liver cancer cohort studyRead Article
In this podcast episode, Drs. Obi and Malachi Griffith, Professors of Medicine at Washington University in St. Louis, MO, discuss their work in improving interpretations of sequence variants in cancer and enhancing bioinformatics education.Listen Now
*Data on file based on a 2013 study.